CHLORPHENIRAMINE PLASMA-CONCENTRATION AND HISTAMINE H-1-RECEPTOR OCCUPANCY

被引:37
作者
YASUDA, SU
WELLSTEIN, A
LIKHARI, P
BARBEY, JT
WOOSLEY, RL
机构
[1] GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007
[2] BIOASSAY LAB INC,HOUSTON,TX
关键词
D O I
10.1016/0009-9236(95)90199-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The plasma concentration-response relationship of the antihistamine chlorpheniramine is poorly characterized. This study examined concurrently the concentrations of chlorpheniramine and presence of H-1-receptor antagonist in plasma after administration of 8 mg chlorpheniramine in normal volunteers. Six extensive metabolizers and five poor metabolizers, as judged by CYP2D6 phenotype (dextromethorphan metabolic ratio), were enrolled in the study. More than 80% occupancy of H-1-receptors by antagonist in plasma was observed for 12 hours after the dose in extensive metabolizers and greater than 60% from 12 to 30 hours in poor metabolizers, when plasma concentrations had fallen below those that should result in 50% occupancy of receptors. The results suggest that (+/-)-chlorpheniramine plasma concentrations do not predict H-1-receptor antagonist in plasma. In addition, a role is suggested for CYP2D6 in formation of a potent active metabolite of chlorpheniramine.
引用
收藏
页码:210 / 220
页数:11
相关论文
共 28 条
[1]  
ARBESMAN CE, 1950, J ALLERGY, V21, P255
[2]   RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY [J].
BUCHERT, ET ;
WOOSLEY, RL ;
SWAIN, SM ;
OLIVER, SJ ;
COUGHLIN, SS ;
PICKLE, L ;
TROCK, B ;
RIEGEL, AT .
PHARMACOGENETICS, 1993, 3 (06) :322-327
[3]  
CHANG RSL, 1979, J PHARMACOL EXP THER, V209, P437
[4]  
CHIOU WL, 1979, NEW ENGL J MED, V300, P501
[5]   PURIFICATION OF [H-3] MEPYRAMINE RECEPTOR FROM RAT-LIVER AND ITS AMINO-ACID-SEQUENCE HOMOLOGY WITH DEBRISOQUINE 4-HYDROXYLASE CYTOCHROME-P-450 [J].
FUKUI, H ;
MIZUGUCHI, H ;
LIU, YQ ;
LEURS, R ;
KANGAWA, K ;
MATSUO, H ;
WADA, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (05) :1727-1728
[6]   SALIVARY ANALYSIS FOR DETERMINATION OF DEXTROMETHORPHAN METABOLIC PHENOTYPE [J].
HOU, ZY ;
PICKLE, LW ;
MEYER, PS ;
WOOSLEY, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (04) :410-419
[7]   PHARMACOKINETICS OF CHLORPHENIRAMINE AFTER INTRAVENOUS AND ORAL-ADMINISTRATION IN NORMAL ADULTS [J].
HUANG, SM ;
ATHANIKAR, NK ;
SRIDHAR, K ;
HUANG, YC ;
CHIOU, WL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (04) :359-365
[8]   BIOAVAILABILITY OF REGULAR AND CONTROLLED-RELEASE CHLORPHENIRAMINE PRODUCTS [J].
KOTZAN, JA ;
VALLNER, JJ ;
STEWART, JT ;
BROWN, WJ ;
VISWANATHAN, CT ;
NEEDHAM, TE ;
DIGHE, SV ;
MALINOWSKI, R .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (08) :919-923
[9]  
MIYAZAKI H, 1976, CHEM PHARM BULL, V24, P2572
[10]   LIGAND - A VERSATILE COMPUTERIZED APPROACH FOR CHARACTERIZATION OF LIGAND-BINDING SYSTEMS [J].
MUNSON, PJ ;
RODBARD, D .
ANALYTICAL BIOCHEMISTRY, 1980, 107 (01) :220-239